Cynthia L. Verst is president of Clinical Operations at Quintiles, a position she was appointed to in 2015. In this capacity, her responsibilities span the clinical development spectrum across the Quintiles organization. Previously, she served as president of Real-World & Late Phase Research at Quintiles.
Verst has more than 20 years of biopharmaceutical industry experience and a proven track record of operational leadership and innovation. Prior to joining Quintiles, she served as senior vice president, Global Late Phase Research, for OptumInsight (a division of UnitedHealth Group, formerly i3), where she and her team successfully established a new global Late Phase Research Business Unit. Previously, Verst and her team established and led Kendle’s global Late Phase Business Unit. She began her career in biopharma at Procter & Gamble Pharmaceuticals as Section Head in its North American Medical and Technical Affairs group, successfully leading the Phase IIIB/IV research requirements of marketed products.
Verst was named one of the top women in biotech in 2014 by FierceBiotech, an annual award that spotlights an elite list of 15 women leaders in the life sciences, academia and regulatory roles.
Verst holds a Pharm.D. and bachelor of science degree in Pharmacy from the University of Cincinnati, a master of science in Structural and Cellular Biology from the University of Illinois, and a bachelor of science degree in Biology and Chemistry from Northern Kentucky University.